FDA
-
-
-
-
-
-
-
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
-
-
-
-
-
-
-
Telomir reports Telomir-1 reduces cellular iron more than approved chelator
-
-
-
-
-
-
-
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
-
-
-
-
-
-
-
Telomir Pharmaceuticals (TELO) Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model
-
-
-
-
-
-
-
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
-
-
-
-
-
-
-
Telomir Pharmaceuticals (TELO) Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
-
-
-
-
-
-
-
Telomir Pharmaceuticals (TELO) Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo
-
323,112 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

